Literature DB >> 26193663

The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy.

Yan-Jie Chen1, Hao Wu1, Xi-Zhong Shen2.   

Abstract

The ubiquitin-proteasome system (UPS) is a complicated tightly controlled system in charge of degrading 80-90% of proteins, and is central to regulating cellular function and keeping protein homeostasis. Therefore, the components of UPS attract considerable attention as potential targets for hepatocellular carcinoma (HCC) therapy. The clinical success of bortezomib in multiple myeloma and mantle cell lymphoma patients has set the precedent for therapeutically targeting this pathway. This review will provide an overview of the UPS in HCC and the current status of therapeutic strategies.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; Inhibitor; Treatment; Ubiquitin–proteasome system

Mesh：

Substances：

Year:  2015        PMID： 26193663     DOI： 10.1016/j.canlet.2015.06.023

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  26 in total

Review 1.  The structure and regulation of the E3 ubiquitin ligase HUWE1 and its biological functions in cancer.

Authors:  Xiaofeng Gong; Danyu Du; Yanran Deng; Yuqi Zhou; Li Sun; Shengtao Yuan
Journal:  Invest New Drugs       Date:  2020-02-01       Impact factor: 3.850

2.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

3.  Evaluation of Apelin/APJ system expression in hepatocellular carcinoma as a function of clinical severity.

Authors:  Manuela Cabiati; Melania Gaggini; Paolo De Simone; Silvia Del Ry
Journal:  Clin Exp Med       Date:  2020-11-17       Impact factor: 3.984

Review 4.  Ubiquitin-proteasome system-targeted therapy for uveal melanoma: what is the evidence?

Authors:  Chen-Xi Zhao; Chen-Ming Zeng; Ke Wang; Qiao-Jun He; Bo Yang; Fan-Fan Zhou; Hong Zhu
Journal:  Acta Pharmacol Sin       Date:  2020-06-29       Impact factor: 6.150

5.  UBE2O Promotes Progression and Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.

Authors:  Xiyu Chen; Shuiting Zhang; Chao Liu; Guo Li; Shanhong Lu; Yunyun Wang; Xin Zhang; Donghai Huang; Yuanzheng Qiu; Yong Liu
Journal:  Onco Targets Ther       Date:  2020-06-29       Impact factor: 4.147

6.  Down-regulation of salt-inducible kinase 1 (SIK1) is mediated by RNF2 in hepatocarcinogenesis.

Authors:  Chao Qu; Yaqin Qu
Journal:  Oncotarget       Date:  2017-01-10

Review 7.  Positioning of proteasome inhibitors in therapy of solid malignancies.

Authors:  Margot S F Roeten; Jacqueline Cloos; Gerrit Jansen
Journal:  Cancer Chemother Pharmacol       Date:  2017-11-28       Impact factor: 3.333

8.  Pekinenin E Inhibits the Growth of Hepatocellular Carcinoma by Promoting Endoplasmic Reticulum Stress Mediated Cell Death.

Authors:  Lu Fan; Qingling Xiao; Yanyan Chen; Gang Chen; Jinao Duan; Weiwei Tao
Journal:  Front Pharmacol       Date:  2017-06-29       Impact factor: 5.810

9.  Low-Grade Dysplastic Nodules Revealed as the Tipping Point during Multistep Hepatocarcinogenesis by Dynamic Network Biomarkers.

Authors:  Lina Lu; Zhonglin Jiang; Yulin Dai; Luonan Chen
Journal:  Genes (Basel)       Date:  2017-10-13       Impact factor: 4.096

10.  Prognostic and predicted significance of Ubqln2 in patients with hepatocellular carcinoma.

Authors:  Yuan-Deng Luo; Hong-Qiang Yu; Xiao-Yu Liu; Deng Huang; Hai-Su Dai; Lei Fang; Yu-Jun Zhang; Jie-Juan Lai; Yan Jiang; Ling Shuai; Lei-Da Zhang; Geng Chen; Ping Bie; Chuan-Ming Xie
Journal:  Cancer Med       Date:  2020-04-15       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.